BeiGene
ONC
#733
Rank
ยฃ19.90 B
Marketcap
ยฃ171.29
Share price
-0.76%
Change (1 day)
61.81%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Cash on Hand

Cash on Hand as of December 2024 : ยฃ1.96 Billion

According to BeiGene 's latest financial reports the company has ยฃ1.96 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31ยฃ2.09 B-15.9%
2023-12-31ยฃ2.48 B-33.58%
2022-12-31ยฃ3.74 B-23.54%
2021-12-31ยฃ4.90 B43.69%
2020-12-31ยฃ3.41 B355.26%
2019-12-31ยฃ0.74 B-46.6%
2018-12-31ยฃ1.40 B126.47%
2017-12-31ยฃ0.61 B107.68%
2016-12-31ยฃ0.29 B340.04%
2015-12-31ยฃ67.8 M137.8%
2014-12-31ยฃ28.51 M1098.06%
2013-12-31ยฃ2.38 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
ยฃ12.24 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.32 B-83.56%๐Ÿ‡บ๐Ÿ‡ธ USA